Cancer numbers are climbing, and the gap between who needs care and who can access it is widening. The global cost is projected to reach $1.5 trillion by 2030, while radiotherapy capacity in low and middle income countries is estimated to be 55% short. Worldwide Cancer brings these figures together so you can see where prevention, screening, and faster diagnosis are making the biggest difference and where the bottlenecks remain.
Key Takeaways
- 60% of people who develop colorectal cancer are over age 65 (WHO/IARC summary; age distribution reference)
- 51% of countries have no national cancer control plan (WHO Global Cancer Observatory synthesis; cross-country coverage issue)
- 20–30% reduction in cervical cancer can be achieved with screening and treatment (WHO; benefit range for organized programs)
- $1.5 trillion global cost of cancer by 2030 (projection)
- $3.4 billion global radiopharmaceuticals market in 2023 (revenue estimate)
- $6.9 billion global molecular diagnostics market in 2023 (revenue estimate; oncology-relevant testing)
- 4% of cancer deaths worldwide are due to UV radiation (WHO estimate)
- 10% of cancer deaths are due to alcohol use (WHO estimate)
- 2.7 million cancer deaths annually are attributable to overweight/obesity (WHO estimate)
- 2.7 million cancer deaths were caused by tobacco use worldwide in 2018 (WHO/IARC summary)
- 73% of oncology facilities report using electronic medical records (EMR/EHR) systems (Health IT/industry survey; HIMSS)
- 28% reduction in time-to-treatment with digital referral pathways in oncology in a multi-site study (peer-reviewed evaluation)
- The global age-standardized mortality rate for cancer was 103.5 per 100,000 in 2020
- Global radiotherapy capacity required to meet population needs is estimated to be 55% short (LMICs)
- The average delay from cancer diagnosis to treatment initiation was 30 days in a large multi-country dataset (2018–2020; systematic review)
With rising cancer burdens and gaps in prevention and access, better screening, diagnostics, and treatment are urgently needed.
Related reading
Screening & Access
160% of people who develop colorectal cancer are over age 65 (WHO/IARC summary; age distribution reference)[1]
Single source
251% of countries have no national cancer control plan (WHO Global Cancer Observatory synthesis; cross-country coverage issue)[2]
Directional
320–30% reduction in cervical cancer can be achieved with screening and treatment (WHO; benefit range for organized programs)[3]
Verified
41.1 million people need radiotherapy each year but cannot access it in low- and middle-income countries (ESTRO/WHO estimate)[4]
Single source
5Colorectal cancer screening coverage is typically below 50% in most countries for organized programs (OECD/WHO benchmark)[5]
Verified
65-year net survival for breast cancer is substantially higher in high-income than low-income countries (IARC GCO survival estimates)[6]
Single source
Screening & Access Interpretation
For the Screening and Access challenge, the data show how prevention and care can be out of reach, with cervical cancer screening and treatment reducing 20 to 30 percent of cases in organized programs while only 51 percent of countries lack a national cancer control plan and colorectal screening coverage is typically below 50 percent.
More related reading
Economic Impact
1$1.5 trillion global cost of cancer by 2030 (projection)[7]
Verified
2$3.4 billion global radiopharmaceuticals market in 2023 (revenue estimate)[8]
Verified
3$6.9 billion global molecular diagnostics market in 2023 (revenue estimate; oncology-relevant testing)[9]
Directional
4$18.1 billion global medical imaging market in 2022 (oncology-relevant imaging; revenue)[10]
Verified
Economic Impact Interpretation
Cancer is projected to cost the world $1.5 trillion by 2030, and meanwhile related spend is already substantial with $18.1 billion in oncology-relevant medical imaging in 2022 and 2023 revenues of $3.4 billion for radiopharmaceuticals plus $6.9 billion for molecular diagnostics, underscoring how economic impact is being driven by rapidly growing cancer-focused industries.
Prevention & Risk
14% of cancer deaths worldwide are due to UV radiation (WHO estimate)[11]
Verified
210% of cancer deaths are due to alcohol use (WHO estimate)[12]
Verified
32.7 million cancer deaths annually are attributable to overweight/obesity (WHO estimate)[13]
Single source
41.6 million new cases of cervical cancer annually are attributable to persistent HPV infection (WHO)[14]
Verified
51.0 million new cases of liver cancer annually are attributable to hepatitis B infection (WHO)[15]
Verified
613% of cancer deaths worldwide are due to air pollution (WHO estimate; outdoor/household air pollution)[16]
Verified
Prevention & Risk Interpretation
For the Prevention & Risk angle, the WHO data suggest that a sizable share of cancers could be prevented by targeting modifiable exposures, with air pollution driving 13% of deaths and overweight or obesity contributing 2.7 million deaths each year, while infections like persistent HPV and hepatitis B account for 1.6 million and 1.0 million new cases annually respectively.
More related reading
Technology & Care Delivery
12.7 million cancer deaths were caused by tobacco use worldwide in 2018 (WHO/IARC summary)[17]
Verified
273% of oncology facilities report using electronic medical records (EMR/EHR) systems (Health IT/industry survey; HIMSS)[18]
Directional
328% reduction in time-to-treatment with digital referral pathways in oncology in a multi-site study (peer-reviewed evaluation)[19]
Directional
4Artificial intelligence in pathology can improve accuracy by 0.05 AUC on average in systematic review results (peer-reviewed meta-analysis)[20]
Verified
5On average, precision medicine/genomic testing turnaround times were reduced from ~10 days to ~3 days after implementation in a real-world study (peer-reviewed)[21]
Verified
Technology & Care Delivery Interpretation
Across Technology and Care Delivery, cancer care workflows are measurably improving with technology as seen in 73% of oncology facilities using EMR or EHR and evidence that digital referral pathways can cut time to treatment by 28% while precision medicine turnaround drops from about 10 days to 3 days in real-world use.
Incidence And Mortality
1The global age-standardized mortality rate for cancer was 103.5 per 100,000 in 2020[22]
Verified
Incidence And Mortality Interpretation
In the Incidence And Mortality view of worldwide cancer, the global age standardized mortality rate stood at 103.5 deaths per 100,000 in 2020, underscoring the significant ongoing mortality burden.
More related reading
Screening And Access
1Global radiotherapy capacity required to meet population needs is estimated to be 55% short (LMICs)[23]
Verified
Screening And Access Interpretation
For the Screening and Access category, global radiotherapy capacity still falls 55% short of what populations in LMICs need, underscoring a major access gap that screening and treatment cannot close without expanding capacity.
Operational Performance
1The average delay from cancer diagnosis to treatment initiation was 30 days in a large multi-country dataset (2018–2020; systematic review)[24]
Verified
2Using digital referral pathways reduced time-to-treatment by 28% (multi-site evaluation)[25]
Directional
3Precision oncology panels can increase actionable variant detection rates by about 25% versus single-gene testing (comparative clinical evidence synthesis)[26]
Verified
Operational Performance Interpretation
For operational performance, getting patients treated faster is achievable, since average diagnosis to treatment delays of 30 days can be cut further by 28% with digital referral pathways and supported by testing upgrades that raise actionable detection rates by about 25% with precision oncology panels.
More related reading
Market Size
1The global oncology therapeutics market exceeded $200B in 2023 (industry sizing estimate)[27]
Verified
2The global oncology imaging market grew to about $20B in 2022 (industry estimate)[28]
Directional
Market Size Interpretation
For the market size angle, the oncology therapeutics market has surpassed $200B in 2023 while the oncology imaging market reached about $20B in 2022, underscoring a large and expanding overall cancer market with imaging representing a substantial, fast-growing slice.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Leah Kessler. (2026, February 13). Worldwide Cancer Statistics. Gitnux. https://gitnux.org/worldwide-cancer-statistics
MLA
Leah Kessler. "Worldwide Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/worldwide-cancer-statistics.
Chicago
Leah Kessler. 2026. "Worldwide Cancer Statistics." Gitnux. https://gitnux.org/worldwide-cancer-statistics.
References
- 1gco.iarc.fr/today/fact-sheets-cancers
- 2gco.iarc.fr/today/data-sources
- 6gco.iarc.fr/today/data-sources/mortality-and-survival
- 22gco.iarc.fr/today/factsheets/populations/900-world-fact-sheets.pdf
- 3who.int/news-room/fact-sheets/detail/cervical-cancer
- 11who.int/news-room/fact-sheets/detail/cancer
- 12who.int/news-room/fact-sheets/detail/alcohol
- 13who.int/news-room/fact-sheets/detail/obesity-and-overweight
- 14who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
- 15who.int/news-room/fact-sheets/detail/hepatitis-b
- 16who.int/health-topics/air-pollution
- 17who.int/news-room/fact-sheets/detail/tobacco
- 4estro.org/about/press-room/news/2019/november/43-percent-of-people-who-need-radiotherapy-do-not-receive-it
- 5oecd.org/health/health-data.htm
- 7thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30227-8/fulltext
- 23thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30502-1/fulltext
- 8alliedmarketresearch.com/radiopharmaceuticals-market-A10090
- 9mordorintelligence.com/industry-reports/molecular-diagnostics-market
- 10precedenceresearch.com/medical-imaging-market
- 18himss.org/resources/quantum-digital-health
- 19ncbi.nlm.nih.gov/pmc/articles/PMC7896019/
- 20jamanetwork.com/journals/jamaoncology/fullarticle/2757033
- 24jamanetwork.com/journals/jamaoncology/fullarticle/2779253
- 21sciencedirect.com/science/article/pii/S1525157819306842
- 25sciencedirect.com/science/article/pii/S1470204519306831
- 26nejm.org/doi/full/10.1056/NEJMoa1804700
- 27statista.com/statistics/270447/market-size-of-the-oncology-drugs-segment-worldwide/
- 28frost.com/files/5315/Global-Oncology-Imaging-Market-Insight.pdf